We describe the isolation and characterization of a cDNA clone, called cCLP-1, that is a candidate for the previously described early cardiac-specific transcription factor BBF-1. BBF-1 binds the MEF2 (or element B) binding site within the cardiac myosin light chain 2 (MLC2) gene promoter. We used the element B sequence as a probe to screen an expression library constructed from mRNA obtained from the presumptive heart-forming regions of stage 6 chicken embryos. This yielded the cCLP-1 cDNA clone. Gel-shift analysis of stage 6 embryonic chicken protein extracts suggests that a protein that is recognized by the anti-cCLP-1 antibody binds to the same element B binding site to which BBF-1 binds. cCLP-1 mRNA was detected early in chicken development, prior to cardiac fate assignment at stage 4. The expression pattern of cCLP-1, based on whole mount in situ hybridization, coincides remarkably well with the established morphogenetic field of early heart formation. The nuclear localization of cCLP-1 is phosphorylation-dependent, suggesting that cCLP-1 may be a member of that class of transcription factors whose activity is regulated by cytoplasm to nucleus transport. Taken together, these data suggest that cCLP-1 may encode a novel transcription factor whose expression pattern is in agreement with that of the cardiogenic precursor cells of the early chicken embryo.
INTRODUCTION
The specification of distinct cell lineages in developing embryos is believed to be determined by regionally restricted lineage-specific transcription factors that influence the expression pattern of downstream tissue-specific genes. Cardiogenic cell lineage assignment is one of the first functional specifications to occur during development (DeHaan, 1965; Kessler and Melton, 1994; Antin et al., 1994) . In avian embryos, the cardiogenic precursor cells of mesodermal origin populate areas on either side of the anterior primitive streak during gastrulation at stage 4 (Hamburger and Hamilton, 1951) . These cells migrate rostromedially and coallesce to form the cardiac primordia which then begins to express myofibrillar proteins leading to formation of a functionally beating tubular heart at stage 10 (ϳ33 h of development) (Rosenquist and DeHaan, 1966) . Cardiac cell commitment itself is perceived as a progressive process involving inductive signals originating from axial tissues, the hypoblast, and subsequently from the anterior endoderm (Rosenquist and DeHaan, 1966; Azar and EyalGiladi, 1979; Garcia-Martinez and Schoenwolf, 1993; Montgomery et al., 1994; Nascone and Marcola, 1995; Yatskievych et al., 1997) . Cells derived from stage 4, but not stage 3, differentiate into myocytes, suggesting that cardiac specification occurs at stage 4, even though cardiogenic origin is traceable to the mesoderm of earlier stages (Mikawa et al., 1992; Linsak and Lash, 1993; Montgomery et al., 1994) . This would suggest that despite some level of commitment of early mesodermal cells, a second inductive state is required for cardiac differentiation. The complex and progressive nature of the inductive interactions whereby a mesodermal cell becomes committed to the cardiac cell lineage is therefore likely to involve a number of regulatory factors (Azar and Eyal-Giladi, 1979; GarciaMartinez and Schoenwolf, 1993; Montgomery et al., 1994) .
The complex network of regulatory factors responsible for the skeletal myogenic program has been relatively well characterized, but the regulatory mechanisms underlying cardiogenic development are poorly understood (see Olson et al., 1995; Mably and Liew, 1996; Goswami and Siddiqui, 1996, for review) . Recently, several genes that are expressed in either mesodermal precursors of cardiac myoblasts or in differentiated cardiomyocytes have been identified and implicated in the regulation of cardiac development. For example, the murine homologs of the Drosophila tinman gene, Nkx 2.5 (Lints et al., 1993) and Csx (Komuro and Izumo, 1993) , are essential for heart development (Bodmer, 1995; Azpiazu and Frasch, 1993) and play a role in the differentiation of the vertebrate cardiac cell lineage (Lyons et al., 1995a) . The avian homolog of Nkx 2.5 (cNkx 2.5) appears in cardiac progenitors as early as stage 5 (Schultheiss et al., 1995) , but is also present in the adult heart (Lyons et al., 1995a) . A novel subclass of bHLH proteins, called dHAND and eHAND, identified in both avian (Srivastava et al., 1995) and murine embryonic development (Hollenberg et al., 1995; Cross et al., 1995) , is expressed in various developing tissues of ectodermal as well as mesodermal origin and detected at stage 8 in chick development. These genes also contribute to the formation of the adult heart and its conduction system. Of the GATA family of transcription factors, which are also candidate regulators of cardiogenesis (Kelley et al., 1993; Jiang and Evans, 1996) , GATA 4 is expressed in precardiogenic cells (Grepin et al., 1994) and may play a role in the morphogenic folding of early cardiac tissues (Kuo et al., 1997; Molkentin et al., 1997) . The myocyte enhancer factors, or MEF2 proteins, are members of the MADS family of proteins and important regulators of early cardiogenesis . During mouse embryogenesis, MEF2 expression marks the cardiac and skeletal as well as neuronal cell lineages (Edmondson et al., 1994; Lyons et al., 1995) . The fact that multiple isoforms of MEF2 proteins exist which bind to functional DNA sites as dimers points to their potential in executing diverse functions in the regulation of gene transcription. A direct interaction between MEF2 and MyoD proteins is evident in activation of skeletal muscle gene expression (Molkentin et al., 1995; Kaushal et al., 1994) , suggesting that the interplay between members of the MEF2 family and bHLH proteins might be important for expression of skeletal muscle genes. Such a cooperation between MEF2 family members and the concomitantly expressed Nkx2.5/Csx homeobox genes has been suggested as one mechanism that underlies the onset of cardiogenic differentiation .
Despite the wealth of information on the cardiac regulatory factors described above, none of them were detected, at least in avian embryos, in cardiac progenitor cells in stages of development prior to cardiac fate assignment (stage 4), a criterion in accord with the expected role of regulator(s) of the cardiac cell lineage. We have previously reported that the binding activity of a cardiac-specific transcription factor, BBF-1, which recognizes the MEF2 site in the cardiac MLC-2 promoter (Zhou et al., 1993) , appears in chicken blastoderms as early as stage 4, prior to the onset of cardiogenic gene expression (Goswami et al., 1994) . The early expression of BBF-1 and late expression of CMD-1, the chicken homolog of MyoD (Lin et al., 1989) , in avian development are consistent with the established patterns of cardiac and skeletal morphogenetic development, respectively, and provide a compelling argument in favor of the role of BBF-1 in regulation of early cardiac development (Goswami et al., 1994; Goswami and Siddiqui, 1996) .
In this report, we describe the isolation and characterization of a novel cDNA clone, pCLP-1 (cardiac lineageassociated protein), a candidate clone for BBF-1 that is able to bind the MEF2 or element B site within the cardiac MLC2 gene promoter and whose early expression pattern in chicken embryos coincides with the heart-forming cardiogenic regions of the stage 4 -6 chicken embryo.
MATERIALS AND METHODS
Isolation of cCLP-1 cDNA clone from stage 6 heart-forming region cDNA library. Fresh fertilized White Leghorn eggs, purchased from Spafas (Norwich CT), were incubated at 37.5°C and allowed to develop to stage 6 (Hamburger and Hamilton, 1951) . Eggs were opened in Howard's chick saline and the stage 6 embryos identified under dissecting microscope were dissected to isolate heart-forming region tissue. mRNA was isolated using the Microfast Track kit (Invitrogen) and the cDNA library was customconstructed in the ZAP Express vector (Stratagene). Expression screening of the library was carried out using an MLC2 promoter element B (MEF2 site) hexamer as probe [(GACATGGGGT-TATTTTTAGCCTGGAATGGG)6] (Goswami et al., 1994) in procedures described by Singh et al. (1989) . All subsequent molecular biological procedures were carried out in accord with standard practices (Sambrook et al., 1987) .
Gel mobility shift assays. Gel mobility shift assays were performed as described earlier (Zhou et al., 1993; Goswami et al., 1994) . Double-stranded DNA fragments obtained by renaturation of chemically synthesized oligonucleotides (GACATGGGGT-TATTTTTAGCCTGGAATGGG) were radiolabeled at the 5Ј end by polynucleotide kinase and [␥-32 P]ATP and used for the binding assay. DNA probe (5,000 cpm) and nuclear proteins or cell extracts were incubated in 10 mM Hepes (pH 7.9), 80 mM NaCl, 5 mM MgCl 2 , 0.5 mM EDTA, 1 mM DTT, 12.5% glycerol at 4°C for 90 min and separated on a 6% polyacrylamide gel. For immunoprecipitation assays, anti-CLP-1 antiserum and anti-MEF2 antiserum were preincubated with cell extracts for 30 min at 4°C before addition of the DNA probe.
Northern and Western blot analysis. Total RNA was isolated from embryos of defined stages using RNAZol as per the manufacturer's protocol (Tel Test Inc., Friendswood, TX) . RNA (20 g per lane) was fractionated by formaldehyde agarose gel electrophoresis and transferred onto nylon membranes by downward capillary transfer in 20ϫ SSC as per manufacturer's instructions (Schleicher and Schuell). cCLP-1 cDNA was radiolabeled to a high specific activity (1.4 ϫ 10 9 cpm/g) and used for hybridization at 42°C for 16 h. After stringent washes (final wash: 3ϫ in 0.1ϫ SSC, 0.2% SDS, 60°C, 20 min) the filter was exposed to X-ray film. For Western blot analysis of recombinant CLP-1 and proteins from other tissues, protein extracts were isolated by homogenization in 0.1 M NaCl, 0.01 M Tris-Cl, pH 7.6, 0.001 M EDTA, 1 mg/ml aprotinin, and 100 mg/ml PMSF. Proteins were fractionated by 12% SDS-PAGE and visualized by Western blotting (Towbin et al., 1979) using the CLP-1 antiserum and the ECL Western blot developing reagent (Amersham) according to the manufacturer's protocol.
Whole mount in situ hybridization. Whole mount in situ hybridization was performed according to Harland (1991) and Izpisua-Belmonte et al. (1993) . Chick embryos were staged according to Hamburger and Hamilton (1951) and fixed in MEMPHA (0.1 M Mops pH 7.4, 2 mM EDTA, 1 mM MgSO 4 3.7% formaldehyde), treated with 10 mg/ml proteinase K (Sigma) and postfixed in 4% paraformaldehyde and 0.25% glutaraldehyde. Digoxigenin-labeled sense and antisense riboprobes were prepared from the linearized pCLP-1 DNA, 186-bp MLC2-specific subcloned PCR-amplified DNA, and cNkx2.5 (kindly provided by T. Schultheiss) with T3 and T7 RNA polymerase. Hybridization was carried out overnight at 70°C. After stringent washes (2ϫ Solution I: 50% formamide, 5ϫ SSC, pH 4.5, 1% SDS, 70°C for 30 min; 3ϫ in Solution II: 0.5 M NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% Tween 20 at 70°C for 10 min; 2ϫ Solution II: 100 mg/ml RNase A for 30 min at 37°C; 2ϫ Solution III: 50% formamide, 2ϫ SSC, pH 4.5, 60°C for 30 min) embryos were treated with Levamisole and 10% heat-inactivated nonspecific serum in TBST. Embryos were then incubated overnight in anti-digoxigenin alkaline phosphatase antibody and detected by chromogenic reaction using NBT and BCIP. Embryos were washed in NTMT, postfixed in 4% formaldehyde and 0.1% glutaraldehyde, dehydrated, and rehydrated to intensify pink to purple color, cleared in glycerol/PBT, 1 mM EDTA, and stored in this solution for photography and histological sectioning.
Cardiac cell culture and immunostaining. Primary cardiac cells were prepared from 13-to 18-day-old embryonic chicken hearts essentially in accord with previously published procedures (Zadeh et al., 1986) . Cells, cultured on chick serum and/or fibronectin-coated coverglasses, were allowed to grow for 24 h and treated with 20 mM dibutyryl cAMP (Sigma) for various lengths of time. Upon completion of treatment, cells were fixed in methanol: acetone (1:1) for 20 min at Ϫ20°C and air-dried. Cells were stained using MF20 (a monoclonal antibody directed against the myosin heavy chain) and polyclonal anti-cCLP-1 antibodies with FITC and TRITC-tagged secondary antibodies, respectively. Cells were observed under epifluorescence using a Leitz Laborlux-S microscope and photographed.
RESULTS

Isolation of a cDNA clone for cardiac lineage-associated protein.
We have reported previously (Goswami et al., 1994) that the first appearance of cardiac-specific gene transcripts, e.g., cardiac MLC2 and ␣-actin, begins at the head process stage (stage 5) in chicken development, immediately after cardiac fate assignment at stage 4, whereas skeletal muscle-specific mRNAs appear at stage 8 of development soon after the formation of the first somite at stage 7. We have also shown that the mRNA for CMD-1, the chicken homolog of MyoD, appears at stage 5, prior to somite formation, consistent with its established role in promoting the skeletal myogenic program. Based on these observations, we based our cloning strategy on the likelihood that gene product(s) involved in promoting the cardiogenic program must be present at or prior to the stage in which mesodermal cells are fated to become cardiogenic (stage 4).
To isolate candidate cardiac lineage-specific gene(s), we attempted to construct a cDNA library from mRNA isolated from the heart forming regions of stage 4 chicken blastoderms. However, due to limitations in obtaining sufficient amounts of mRNA from highly fragile stage 4 blastoderms, we resorted to microdissecting the welldefined heart-forming regions of stage 6 embryos for isolation of poly(A) ϩ RNA. A cDNA expression library was custom-constructed from this poly(A) ϩ RNA (Stratagene Inc.) and screened with a DNA probe consisting of a multimerized copy of the element B (MEF-2 site) present in the chicken MLC-2 promoter (see Materials and Methods). Of the seven candidate cDNA clones obtained, one, cCLP-1, contained the largest insert of 1141 nucleotides. cCLP-1 was selected for further studies and subjected to sequence analysis. The nucleotide sequence along with the deduced amino acid sequence which contains a contiguous polypeptide of 327 amino acids, is shown in Fig. 1 . Northern blot analysis (see below) showed the size of cCLP-1 mRNA to be about 1300 bp, indicating that portions of 3Ј and 5Ј untranslated regions are missing in the cCLP-1 cDNA. Two other plasmids, pCLP-5 (ϳ600 bp) and pCLP-7 (ϳ721 bp) were also sequenced. pCLP-5 was ϳ30% homologus to pCLP-1 and pCLP-7 was identical in sequence to pCLP-1 with a 20-bp extension in the 3Ј-end. The amino acid sequence of cCLP-1 derived from the nucleotide sequence did not reveal defined zinc finger or leucine zipper domains, although a basic amino acid region (underlined), the putative DNA binding domain, was located. Two sequence domains homologous to the cAMP phosphorylation sites (italics) were also noted.
Comparison of the cCLP-1 cDNA sequence in the GenBank database indicated that cCLP-1 has no homology with known MEF2 sequences. However, when the cCLP-1 cDNA sequence was used to search the expressed sequence tagged (EST) database, significant sequence homology was found between cCLP-1 and an EST clone obtained from 19.5 dpc mouse (W34238, 83% homology) and a human EST clone (N43814, 79% homology), indicating that cCLP-1-like transcripts are also expressed in early mammalian development.
Developmental expression of CLP-1 during early chicken development. When total RNA from chicken blastoderms of defined stages 1 through 20 was examined by Northern blot hybridization, trace cCLP-1 signal was detected as early as stage 1 and became more intense at stage 3 onward with peak expression at stages 7-9 when cardiac primordia undergo fusion (Fig. 2) . The presence of a cCLP-1-positive signal at stages prior to cardiac fate assignment (stage 4) is noteworthy and supports the notion that the origin of cardiogenic cell precursors can be traced to the mesoderm of embryos earlier than stage 4 (Mikawa et al., 1992; Khaner, 1993; Linsak and Lash, 1993; Montgomery et al., 1994) .
The expression pattern of cCLP-1 mRNA was examined by whole mount in situ hybridization using a digoxigeninlabeled antisense cCLP-1 riboprobe. As shown in Fig. 3B , cCLP-1 specific stain was present in the lateral plate region in stage 4 embryos where cardiogenic progenitors are known to be localized (Garcia-Martinez and Schoenwolf, 1993) . Some stain was also localized in Hensen's node and the margins of the primitive streak from which cardiac progenitors migrate to the lateral plate. The sense riboprobe (Fig. 3A) served as negative control. As deve lopment proceeds, cCLP-1 mRNA became concentrated in the heart-forming regions of head process-stage embryos, consistent with the established pattern of the movement of cardiac progenitor cells in early cardiac development (Rosenquist and DeHaan, 1966) . cCLP-1 transcripts were highly expressed in the anteromedial part of the cardiogenic plate at the head fold level (Fig. 3D) . At stage 11 (Fig. 3E) , cCLP-1-positive stain was present predominantly in the heart, although some stain appeared in brain and neural tube. Examination of subsequent stages revealed that cCLP-1-positive stain begins to appear in noncardiac tissues, especially in the brain. The presence of cCLP-1 in the neurogenic area is not unexpected because several early pattern-forming genes have been shown to have common cardiogenic and neurogenic origins (see Discussion; see also Landolph and Konicezny, 1995; Buffinger and Stockdale, 1995) .
Transverse sectioning of stage 4 embryos subjected to whole mount in situ hybridization with the cCLP-1 antisense riboprobe shows increased cCLP-1 expression in the lateral plate mesoderm (lpm, double arrowheads) from   FIG. 2 . Northern blot analysis. Total RNA from defined stages of chicken embryos was isolated and fractionated on 1.4% formaldehyde agarose gel with appropriate RNA molecular weight markers. Radiolabeled cCLP-1 cDNA (1.4 ϫ 10 9 cpm/g) was used to hybridize the RNA as described under Materials and Methods. ␤-actin cDNA probe was used as a control to normalize for variability in sample RNA loading (bottom). RNA size markers are indicated on the left. A transverse section passing through the heart-forming region of a stage 4 embryo shows stained cardiogenic precursors in the lateral plate mesoderm (lpm). pam, paraxial mesoderm; end, endoderm; ect, ectoderm. Transverse section of stage 11 embryo passing through the heart (G). In situ hybridization with cCLP-1 riboprobe was performed as in F. H, heart; sm, uncommited somatic mesoderm; sp, splanchnic mesoderm.
which cardiac progenitors are derived (Fig. 3F) . While some stain was seen in intermediate mesoderm, axial and paraxial mesoderm (pam) which give rise to notochord and somites, respectively, were free of stain (area between thick arrows). The low level of stain in ectodermal (ect) and endodermal (end) cells may represent either background stain or a low level of cCLP-1 in these cells at early stages of development. Cross sections of stage 11 embryos hybridized with the cCLP-1 riboprobe (Fig. 3G) showed that cCLP-1 expression was primarily localized in the heart with some expression in the splanchnic mesodermal cells (sp) from which precardiac myocytes originate and in the somatoplure (Sm) as well as where uncommitted myogenic cells reside. No expression was apparent in the notochord, primitive gut, and pharyngeal cells. These expression patterns suggest that CLP-1 is expressed in those regions of earlystage chicken embryos that are actively undergoing cardiogenesis, but as development proceeds cCLP-1 does not appear to be restricted to cardiac tissues alone. Gel mobility shift analysis of chicken embryonic stage 6 extracts. To further examine the properties of cCLP-1, the cDNA was cloned into the pET-29 (ϩ) S-tag expression vector (Novagen, Inc.). This creates a fusion protein between cCLP-1 and an S-tag peptide that allows for purification of recombinant cCLP-1 using S-tag-S-protein affinity chromatography. Bacterially produced cCLP-1-S-tag fusion protein was affinity purified according to instructions of the supplier (Novagen, Inc.) and the purified recombinant cCLP-1 protein was used as an immunogen for generation of a rabbit polyclonal antiserum. The anti-cClp-1 antiserum was tested by Western blot analysis using protein lysates of 12-day chicken embryonic heart, skeletal muscle, and liver tissues. The antibody showed a positive reaction with a protein in heart lysate (H) (Fig. 4A ). No reactivity with skeletal muscle (M) or liver (L) protein lysates could be detected. The preimmune serum (PIS) served as negative control. Upon prolonged exposure of these immunoblots to film, a positive signal was evident in both skeletal muscle and liver (data not shown). This finding parallels those of our in situ hybridization studies on whole mount embryos (see above) and suggests that low levels of cCLP-1 or a CLP-1-like protein may be expressed in noncardiac tissues in late embryonic development.
To examine whether stage 6 chicken embryos express cCLP-1 protein and whether this protein can bind the element B of the cardiac MLC2 promoter, we performed gel mobility shift analyses of protein extracts taken from stage 6 embryos (Fig. 4B) . Incubation of protein extracts with the element B probe formed several complexes including one complex that migrated with a mobility similar to that of a complex formed by BBF-1 (Goswami et al., 1994) . To determine whether this complex contained cCLP-1 protein, protein extracts from stage 6 embryos were preincubated with the anti-cCLP-1 antiserum and used in parallel gel shift assays with element B DNA (MEF-2 site) as probe. This resulted in the disappearance of the BBF-1 complex along with a partial supershift. The faster migrating complexes, BBF-2 and BBF-3, were unaffected by the antibody treatment (Fig. 4B) . The embryonic stage 6 extracts, as shown previously, do not contain the slower migrating MEF-2 activity, which appears at later stages of development (stages 8 -9, Goswami et al., 1994 ). These results demonstrate that CLP-1 is a BBF-1-like DNA binding factor that is distinct from MEF2.
FIG. 4.
Tissue specificity of anti-cCLP-1 antibody (A). Recombinant cCLP-1 protein and 12-day embryo protein extracts from heart, skeletal muscle, and liver were analyzed by reaction with anti-cCLP-1 antibody (left) and preimmune serum (right). H, heart; M, skeletal muscle; L, liver; cCLP-1 Ab, anti-cCLP-1 antibody; PIS, preimmune serum. Gel mobility shift assay with anti-cCLP antibody (B). Total protein extracts from stage 6 embryos were preincubated with the antibody prior to gel shift assay with element B DNA as described under Materials and Methods. BBF-1 complex which has a mobility similar to that of the BBF-1 complex was selectively disrupted (arrow) without affecting the fast moving complexes, while the preimmune serum (PIS) was ineffective.
Cytoplasmic cCLP-1 is relocated into the nucleus. To determine if cardiomyocytes express cCLP-1, cardiomyocytes isolated from 13-day-old embryonic hearts were cultured in vitro and immunostained with anti-cCLP-1 antiserum. A strong cCLP-1-positive stain was detected in the cultured cardiomyocytes (Fig. 5A ). Cardiomyocytes were identified by counterstaining with antibody to myosin heavy chain (MF20, a kind gift of D. Bader) (Fig. 5B .) The cCLP-1-positive immunostain was found in both the cytoplasm and the nucleus of cardiomyocytes (Fig. 5C ), whereas the myosin-positive stain was restricted to the cytoplasm as expected. It is well established that some regulatory proteins, including a few transcription factors, are cytoplasmically localized and their import to the nucleus occurs in response to developmental signals (Vanderomme et al., 1996) . Nuclear transport is known to involve phosphorylation at the casein kinase II (CK II) target site, but other kinases, such as the cAMP-dependent protein kinase (PKA), are also involved. Since cAMP is a known to be involved in cardiac development in early embryos (Deshpande and Siddiqui, 1976) and cAMP phosphorylation sites are present in cCLP-1, we tested the possibility that addition of dibutyryl cAMP to the culture medium would promote transport of cCLP-1 to the nucleus. Cardiac myocytes obtained from chicken embryonic heart were cultured in the presence of dibutyryl cAMP (20 mM) and the distribution of the cCLP-1 protein was examined by immunological detection as outlined above. As shown in Fig. 6A , the cCLP-1-positive stain was distributed in both the cytoplasm and nucleus, but upon treatment of cardiomyocytes in culture with dibutyryl cAMP for 12 h, there was a dramatic import of cCLP-1 into nuclei (Fig. 6B ). This suggests that cytoplasmic cCLP-1 is functionally transported to the nuclei, perhaps following its phosphorylation (Vanderomme et al., 1996) .
DISCUSSION
Recently, several novel transcription factors have been identified that are expressed in cardiogenic mesodermal cells or in response to the inductive events leading to formation of cardiac muscle. Among these factors are the homeobox protein cNkx2.5 (Schultheiss et al., 1995) , the GATA proteins (Laverriere et al., 1994; Grepin et al., 1994) , a subclass of bHLH motif proteins, dHAND and eHAND (Srivastava et al., 1995) , MEF2C (Edmondson et al., 1994) , and a novel protein, CMF1, that is immunologically related to bHLH family members (Wei et al., 1996) . cNkx2.5, which shares homology with the tinman gene required for Drosophila heart formation (Bodmer 1995; Harvey 1996) , is induced in avian posterior primitive streak cells by anterior lateral endoderm, suggesting that cNkx2.5 is an early marker of cardiogenesis and has a role in cardiac induction (Schultheiss et al., 1995) . Despite these findings, recent evidence suggests that cNkx2.5 may function at later stages of development. For example, in vivo expression of cNkx2.5 begins only at early head-process stages in chicken embryonic development and the null Nkx2.5 mutation in mouse results in heart defects arising later in development than would be expected if it was a functional homolog of the Drosophila tinman gene, where the mutant phenotype exhibits a complete absence of cardiogenic cells (Lyons et al., 1995a) . Other markers of early cardiogenesis such as GATA-4 (Kelley et al., 1993; Kuo et al., 1997; Molkentin et FIG. 5 . CLP-1 is a cardiac myocyte-specific protein. Cultured cardiac myocytes from 13-day embryonic chicken heart were simultaneously stained with polyclonal anti-cCLP-1 antibody (A) and MF20, a monoclonal antibody directed against myosin heavy chain (B). Phase-contrast photograph of the same field is shown in C. Cardiocytes are positive for both anti-CLP-1 and MF20, whereas fibroblasts are negative with both antibodies.
al., 1997), MEF-2C, (Edmondson et al., 1994; Lin et al., 1997) , dHAND and eHAND (Srivastava et al., 1995; , and pCMF1 (Wei et al., 1996) all appear to have an expression pattern that begins only in the postcommitment period of cardiac development (Fig. 7) .
In this report, we describe the isolation and preliminary characterization of a cDNA clone, cCLP-1, that is a candidate for a cardiogenic factor involved in the expression of cardiac-specific genes. Several features of cCLP-1 suggest that it may be involved in the early stages of cardiogenesis, perhaps as a transcription factor either directly on indirectly affecting the expression of cardiogenic genes. First, the cDNA library expression screening procedure that yielded the cCLP-1 cDNA clone was designed to isolate cardiogenic transcription factors; the probe used consisted of a known myogenic DNA binding site, the MEF2 or B element binding site from the cardiac MLC2 gene promoter, and the cDNA library screened was derived from the early heart-forming region of stage 6 chicken embryos. Together, these two parameters should strongly bias potential positive clones to the cardiogenic class of transcription factors.
Second, both Northern blot and in situ hybridization data suggest that the early expression of cCLP-1 in stage 4 chicken embryos onward is preferentially enriched in regions of the embryo undergoing cardiogenesis. Northern blot analysis shows that cCLP-1 is expressed during the earliest stages of chicken embryonic development with peak expression occurring during heart tube fusion stages (around stages 7-9). In situ hybridization studies localized cCLP-1 expression to cardiogenic regions of the embryo, such as the anteromedial region, and also indicated expression in areas from which migratory cardiogenic precursor cells arise such as the margins of the primitive streak. Together, these data provide evidence for the expression of cCLP-1 in cells derived from regions of the embryo from which cardiogenic precursors arise both prior to and during periods of active cardiogenesis.
Third, gel-shift analysis using protein extracts of stage 6 chicken embryos shows that cCLP-1 binds the MEF2 binding site (element B) of the cardiac MLC2 gene promoter (confirming our expression screening protocol that originally yielded the cCLP-1 cDNA clone). In similar gel-shift analyses of nuclear extracts of cardiomyocytes, typically three predominant complexes are formed: BBF-1, BBF-2, and BBF-3. Using specific cCLP-1 antibody to disrupt formation of putative cCLP-1-element B complexes led to the specific ablation of the BBF-1 complex, suggesting that cCLP-1 in stage 6 chicken embryos is mediating BBF-1 binding activity.
Fourth, cCLP-1 protein can be detected in cultured cardi- Srivastava et al., 1995; (6) Wei et al., 1996. omyocytes by immunohistochemistry using the specific anti-cCLP-1 antiserum which we generated against recombinant cCLP-1. This provides further evidence that the cCLP-1 cDNA clone derived from the stage 6 heart-forming region cDNA library encodes a bonafide cardiac protein detectable in cardiomyocytes isolated from embryonic heart. Interestingly, the cellular localization of cCLP-1 appears to be controllable; phosphorylation of cCLP-1 stimulates the transport of cCLP-1 from the cytoplasm to the nucleus. This is similar to a number of transcription factors whose nuclear localization is also phosphorylation state-dependent, raising the possibility that cCLP-1 may also be a transcription factor whose activity is likewise dependent on phosphorylation state and cellular localization. Taken together, these data provide evidence that the cCLP-1 cDNA clone that we have isolated is a novel protein expressed in the earliest cardiogenic precursor cells of the chicken embryo. cCLP-1 can bind an important regulatory element found in the promoter of the cardiac MLC2 gene, suggesting that it is an important component of the transcriptional machinery required for MLC2 gene transcription. The expression of cCLP-1 in cardiogenic precursor cells raises the possibility that the transcriptional properties of cCLP-1 may not be limited to myofibrillar proteins such as cMLC2 that are expressed late in the cardiogenic program, but may also be directed to early cardiogenic genes as well. We are presently addressing this possibility experimentally by assessing the effects of antisense ablation of cCLP-1 mRNA on early cardiogenic genes such as cNkx2.5 and structural genes such as vMLC2. Preliminary results show that cNkx2.5 and vMLC2 mRNAs are absent in chicken embryos treated with antisense cCLP-1 oligonucleotides (unpublished observations).
While cCLP-1-positive staining is restricted predominantly to cardiogenic regions of the chicken embryo, a broader expression pattern was evident in later stages of development with cCLP-1 expression found in the notochord, brain, and neural fold areas (data not shown). This is not inconsistent with the expression patterns of other candidate cardiogenic regulators. For instance, transcripts of cNkx2.5 also appear in other tissues in late development, such as foregut and pharyngeal regions (Schultheiss et al., 1995) . The MEF-2 family proteins have also been shown to play a role in differentiation of both cardiac and nervous systems (Edmondson et al., 1994; Lyons et al., 1995; . Likewise, the chicken regulatory protein, EAP3000, is expressed during early development of the heart but is also associated with differentiation of the neural crest cells as well (McCabe et al., 1995) . The chicken neurogenic gene, c-serrate-1, is expressed in both central nervous system and the heart (Myat et al., 1996) and its counterpart in rat, jagged, inhibits differentiation of cultured myoblasts by down-regulation of myogenin gene expression (Lindsell et al., 1995) . It appears that the neurogenic cells of early embryos sequester molecules important for cardiac differentiation (Climent et al., 1995; see Landolph and Konieczny, 1995, for review) .
Based on the available evidence, cCLP-1 has properties indicative of a transcription factor involved in both early and late cardiogenic gene expression. We are presently testing the possibility that cCLP-1 is a bonafide transcription factor by assessing the ability of cCLP-1 to transactivate reporter genes under the control of MEF2 (or element B) gene promoter elements. Given our current understanding that some transcription factors cooperate with other factors to fully activate transcription, it is likely that cCLP-1 will also require similar interactions to activate transcription of cardiac genes. Evidence for this occurring in early cardiac gene expression already exists. For example, cooperation between MEF-2 and Nkx family members and Nkx and SRF (serum response factor) transcription factors appears necessary for cardiac myogenesis (Croissant et al., 1996) . It is noteworthy that we have been able to locate, using MEF-2-specific gene primers, MEF-2 transcripts as early as stage 2/3 of chicken development (Goswami et al., 1994 ). Yet, the DNA binding activity of at least one complex bound to the MEF-2 site with slow mobility, characteristic of MEF-2s in several species, appears only late at stage 8, while other complexes, including BBF-1, appear as early as stage 4 of development, indicating that MEF-2 and BBF-1/cCLP-1 are functionally distinct (Goswami et al., 1994) . Since multiple members of regulatory protein families have been implicated in cardiac specification, some perhaps with overlapping functions, a combinatorial role for cCLP-1 in partnership with other factors, such as Nkx family members, is not inconceivable. Further characterization of cCLP-1 based on genetic manipulation of cCLP-1 in other vertebrates, presently in progress in our laboratory, will be required to fully understand the regulatory cross-talk between transcription factors which control early heart development.
Note added in proof.
A recent search of the Genbank database sequences showed that a portion of cCLP-1 has significant (Ӎ 90%) homology with the human vascular smooth muscle inducible protein (HIS1) sequence, but in the codon reading frame other than shown in Fig. 1 above. 
